Baxter International, Inc.
One Baxter Parkway
About Baxter International, Inc.
Baxter touches millions of lives every day. Our products and services are essential building blocks of healthcare.
You’ll find Baxter’s products and therapies on nearly every floor, in every department, in almost every hospital worldwide. You’ll find us in clinics and in the home. Patients and providers rely on Baxter for lifesaving renal and medical products, including intravenous (IV) solutions, systems and administrative sets, IV infusion parenteral nutrition, perioperative care, pharmacy devices and software, acute renal care, and home and in-center dialysis.
Our mission to save and sustain lives inspires our work and our commitment to expanding access to care, providing cost-effective healthcare solutions, delivering quality products and advancing innovations for the world.
Our commitment to our mission means we are there when patients and healthcare professionals need us, during the critical moments that matter most.
CEO: José (Joe) E. Almeida
CMO: James R. Gavin III
CTO: Uma Chowdhry
CFO: Peter Hellman
Please click here for Baxter job opportunities.
FOLLOW BAXTER INTERNATIONAL:
Tweets by Baxer International
742 articles with Baxter International, Inc.
Baxter Unveils New Products at the ASMBS – Obesity Week Meeting to Help Surgeons Overcome Challenges During Bariatric Surgery
Peri-Strips Circular with Secure Grip technology provides several advantages in application and patient outcomes
The indicated annual dividend rate is $0.76 per share of common stock.
Baxter Highlights Data at ISPOR Europe 2018 on Clinical and Economic Benefits When Addressing Malnutrition, Intraoperative Bleeding
Baxter International Inc. (NYSE:BAX), a leading global medical products company, is presenting four health economics and outcomes research (HEOR) analyses this week at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 meeting.
Baxter Introduces New Tisseel Prima Syringe at 2018 American Association of Gynecologic Laparoscopists Meeting
Next-generation syringe provides physicians with enhanced speed, precision and control during surgery
Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at Citi’s 2018 Global Healthcare Conference on Thursday, December 6, 2018, in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 11:45 a.m. EST.
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2018 and updated its full-year 2018 financial outlook.
Baxter Highlights Clinical Data at ASN: Kidney Week Showing How New Technologies Are Advancing Dialysis Care across Modalities
Thirteen studies presented on HDx therapy enabled by Theranova adding to significantly growing global clinical evidence
Baxter Receives CE Mark for PrisMax, the Next-Generation System for Continuous Renal Replacement and Organ Support Therapies
Innovative features inspired by clinician feedback make delivering therapy simpler and more efficient
Baxter Announces U.S. Regulatory Filing for PrisMax Acute Care System and Presentation of 15 Abstracts to Start ASN: Kidney Week 2018
PrisMax incorporates advanced technology for continuous renal replacement therapy (CRRT) designed to increase accuracy and performance for critically ill patients
Baxter to Showcase Critical Care Innovation at the 2018 European Society of Intensive Care Medicine Congress
Product innovations with recent approvals across Baxter’s Acute Therapies, Clinical Nutrition and Medication Delivery businesses to be featured
Today the American Society for Parenteral and Enteral Nutrition (ASPEN), an organization which drives the science and practice of clinical nutrition, and Baxter International Inc.
Baxter and Mayo Clinic Announce Collaboration to Establish Renal Care Center of Excellence in the U.S.
Collaboration combines the clinical expertise of Mayo Clinic and Baxter Renal Care Services
Baxter Collaborates with University of Southern California Center for Body Computing to Advance Digital Health Solutions
Focuses on digital health initiatives intended to improve health outcomes and drive increased efficiency
Baxter Announces U.S. FDA Clearance of ALTAPORE Bioactive Bone Graft in Posterolateral Spine Surgery
Specially designed to enhance and accelerate bone growth with proprietary silicate-substituted technology and optimized micro and macro porosity
Baxter International Inc. today announced that it has been named to Working Mother magazine’s 2018 ‘100 Best Companies’ list.
Baxter International Inc. will host a conference call to discuss its third quarter 2018 financial results on Wednesday, October 31, 2018, at 7:30 a.m. Central Time.
Polyganics Strengthens Global Distribution Network with Appointment of Synovis MCA as US-wide Distributor of NEUROCAP®
Polyganics today announced that it has signed an agreement with Synovis Micro Companies Alliance Inc. to be the exclusive distributor of its nerve capping device, NEUROCAP®, in the US.
Ready-to-use synthetic bone graft substitute designed for ease of use and fast application
Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion System for the United Kingdom, Ireland, Australia and New Zealand
Delivers a state-of-the-art system with proven Dose IQ Safety Software to help elevate the standard of patient safety
Second-quarter revenue of $2.8 billion increased 9 percent on a reported basis and 4 percent on an operational basis